SCHEMBL10003381

SCHEMBL10003381

CCOC(=O)c1c(O)c2nc(OCc3ccccc3)c(CC)cc2n1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ GAA P10253 4/20 0.42
▸ MAPT P10636 4/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ PKM P14618 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ HPGD P15428 1/20 0.41
▸ PPIA P62937 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ MAOB P27338 2/20 0.38
▸ ATP4A P20648 1/20 0.38
▸ ATP4B P51164 1/20 0.38
▸ SRD5A2 P31213 1/20 0.38
▸ JMJD6 Q6NYC1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10002969 0.89 KMT2A (0.44) ALDH1A1KMT2AGAAMAPTKDM4E
SCHEMBL10004160 0.85 ALDH1A1 (0.42) ALDH1A1KMT2AGAAMAPTKDM4E
SCHEMBL10004428 0.84 ALDH1A1 (0.41) ALDH1A1KMT2AGAAMAPTKDM4E
SCHEMBL10002985 0.75 SRD5A2 (0.39) ALDH1A1KMT2AGAAMAPTPKM
SCHEMBL10002954 0.73 KMT2A (0.47) ALDH1A1KMT2AMAPTKDM4ELMNA
SCHEMBL10003005 0.73 MEN1 (0.47) ALDH1A1KMT2AMAPTKDM4ELMNA
SCHEMBL5901336 0.72 PPIA (0.47) ALDH1A1KMT2AMAPTMEN1HSP90AA1
SCHEMBL10003357 0.71 ALDH1A1 (0.45) ALDH1A1KMT2AGAAMAPTKDM4E
SCHEMBL10003358 0.71 MEN1 (0.45) ALDH1A1KMT2AGAAMAPTLMNA
SCHEMBL3061341 0.69 MEN1 (0.50) KMT2AGAAMAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885KMT2A 423/4885GAA 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback